How to translate clinical trial results into gain in healthy life expectancy for individual patients

被引：52

作者：

Dorresteijn, Jannick A. N. ^{[1
]}

Kaasenbrood, Lotte ^{[1
]}

Cook, Nancy R. ^{[2
,3
,4
]}

van Kruijsdijk, Rob C. M. ^{[1
]}

van der Graaf, Yolanda ^{[5
]}

Visseren, Frank L. J. ^{[1
]}

Ridker, Paul M. ^{[2
,3
,4
]}

机构：

[1] Univ Med Ctr Utrecht, Dept Vasc Med, POB 85500, NL-3508 GA Utrecht, Netherlands

[2] Harvard Univ, Sch Med, Boston, MA 02115 USA

[3] Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Div Prevent Med, 75 Francis St, Boston, MA 02115 USA

[4] Brigham & Womens Hosp, MA Div Cardiovasc Med, 75 Francis St, Boston, MA 02115 USA

[5] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands

来源：

BMJ-BRITISH MEDICAL JOURNAL | 2016年 / 352卷

关键词：

LOW-DOSE ASPIRIN; CARDIOVASCULAR-DISEASE; PRIMARY PREVENTION; PREDICTION MODEL; RISK; VALIDATION; SURVIVAL;

D O I：

10.1136/bmj.i1548

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Treatment effects from randomised trials are typically expressed as numbers needed to treat to prevent one adverse disease event during a fixed time interval (eg, five or 10 years). In the actual patient, however, many diseases are chronically progressive, despite treatment. Examples are diabetic nephropathy, some types of malignancies, osteoporosis, and atherosclerosis. In these examples, the aim of treatment is not to prevent but to delay the occurrence of symptomatic disease. Thus the actual effect of treatment is gain in disease-free life expectancy

引用

页数：6

共 22 条

[1] Beiser A, 2000, STAT MED, V19, P1495, DOI 10.1002/(SICI)1097-0258(20000615/30)19:11/12<1495::AID-SIM441>3.0.CO
[2] 2-E
[3] Briggs A., 2006, DECISION MODELLING H
[4] Collins R, 2009, LANCET, V373, P1849, DOI 10.1016/S0140-6736(09)60503-1
[5] Alternate-Day, Low-Dose Aspirin and Cancer Risk: Long-Term Observational Follow-up of a Randomized Trial
Cook, Nancy R.
Lee, I-Min
Zhang, Shumin M.
Moorthy, M. Vinayaga
Buring, Julie E.
[J]. ANNALS OF INTERNAL MEDICINE, 2013, 159 (02) : 77 - W32
[6] General cardiovascular risk profile for use in primary care - The Framingham Heart Study
D'Agostino, Ralph B.
Vasan, Ramachandran S.
Pencina, Michael J.
Wolf, Philip A.
Cobain, Mark
Massaro, Joseph M.
Kannel, William B.
[J]. CIRCULATION, 2008, 117 (06) : 743 - 753
[7] Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3)
Deanfield, John
Simpson, Iain
Bradbury, Kirsten
Fox, Keith
Boon, Nick
Winocour, Peter
Feher, Michael
Doherty, Patrick
Buckley, John
Jennings, Catriona
Keenan, Jan
Weissberg, Peter
Knapton, Mike
Williams, Bryan
Poulter, Neil
Stevens, Paul
Taal, Maarten
Grant, Peter
Home, Philip
Sattar, Naveed
Rees, Alan
Neely, Dermot
Wheeler, David
Goldsmith, David
Potter, John
Jackson, Stephen
[J]. HEART, 2014, 100 : 1 - 67
[8] Dehmer SP, ANN INTERN MED
[9] Aspirin for primary prevention of vascular events in women: individualized prediction of treatment effects
Dorresteijn, Johannes A. N.
Visseren, Frank L. J.
Ridker, Paul M.
Paynter, Nina P.
Wassink, Annemarie M. J.
Buring, Julie E.
van der Graaf, Yolanda
Cook, Nancy R.
[J]. EUROPEAN HEART JOURNAL, 2011, 32 (23) : 2962 - 2969
[10] Estimating treatment effects for individual patients based on the results of randomised clinical trials
Dorresteijn, Johannes A. N.
Visseren, Frank L. J.
Ridker, Paul M.
Wassink, Annemarie M. J.
Paynter, Nina P.
Steyerberg, Ewout W.
van der Graaf, Yolanda
Cook, Nancy R.
[J]. BMJ-BRITISH MEDICAL JOURNAL, 2011, 343

← 1 2 3 →